Marinus Pharmaceuticals (NASDAQ:MRNS) Upgraded to Outperform by Oppenheimer
Marinus Pharmaceuticals (NASDAQ:MRNS – Get Free Report) was upgraded by research analysts at Oppenheimer from a “market perform” rating to an “outperform” rating in a note issued to investors on Monday, MarketBeat.com reports. The firm currently has a $6.00 price objective on the biopharmaceutical company’s stock. Oppenheimer’s price objective would suggest a potential upside of […]
More Stories
BMO Capital Markets Lowers Ascot Resources (TSE:AOT) Price Target to C$0.75
Ascot Resources (TSE:AOT – Free Report) had its price objective trimmed by BMO Capital Markets from C$1.25 to C$0.75 in...
Trevena (NASDAQ:TRVN) Coverage Initiated by Analysts at StockNews.com
StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN – Free Report) in a research report report published on Tuesday. The...
Aclaris Therapeutics (NASDAQ:ACRS) Upgraded by BTIG Research to Buy Rating
BTIG Research upgraded shares of Aclaris Therapeutics (NASDAQ:ACRS – Free Report) from a neutral rating to a buy rating in...
Siemens Aktiengesellschaft (OTCMKTS:SIEGY) Rating Lowered to Neutral at Bank of America
Bank of America cut shares of Siemens Aktiengesellschaft (OTCMKTS:SIEGY – Free Report) from a buy rating to a neutral rating...
Origin Agritech (NASDAQ:SEED) Earns Hold Rating from Analysts at StockNews.com
StockNews.com began coverage on shares of Origin Agritech (NASDAQ:SEED – Free Report) in a research note published on Tuesday. The...
ProAssurance (NYSE:PRA) Lowered to Hold Rating by StockNews.com
StockNews.com downgraded shares of ProAssurance (NYSE:PRA – Free Report) from a buy rating to a hold rating in a research...